BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31346888)

  • 1. Nodal Downstaging of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy: Survival Analysis if ypN0 Is Achieved.
    Tang H; Tan L; Wang H; Shen Y; Yin J
    J Gastrointest Surg; 2020 Jul; 24(7):1469-1476. PubMed ID: 31346888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
    Zanoni A; Verlato G; Giacopuzzi S; Motton M; Casella F; Weindelmayer J; Ambrosi E; Di Leo A; Vassiliadis A; Ricci F; Rice TW; de Manzoni G
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):998-1004. PubMed ID: 27480358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.
    Ikoma N; Estrella JS; Hofstetter W; Das P; Minsky BD; Ajani JA; Fournier KF; Mansfield P; Badgwell BD
    Ann Surg Oncol; 2018 Jul; 25(7):2012-2017. PubMed ID: 29748883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
    Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
    J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Depypere L; De Hertogh G; Moons J; Provoost AL; Lerut T; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Ann Thorac Surg; 2021 Dec; 112(6):1847-1854. PubMed ID: 33352178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation.
    Chen JX; Lu TY; Fang HY; Lin YS; Lee JM
    World J Surg; 2020 Jul; 44(7):2323-2331. PubMed ID: 32296872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer.
    Stark AP; Blum MM; Chiang YJ; Das P; Minsky BD; Estrella JS; Ajani JA; Badgwell BD; Mansfield P; Ikoma N
    J Gastric Cancer; 2020 Sep; 20(3):313-327. PubMed ID: 33024587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer.
    Brinkmann S; Noordman BJ; Hölscher AH; Biermann K; van Klaveren D; Bollschweiler E; Pütz K; van Lanschot JJB; Drebber U
    Ann Surg Oncol; 2020 Apr; 27(4):1250-1258. PubMed ID: 31691114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Lymph Node Yield Is Associated with Prolonged Survival after Neoadjuvant Chemotherapy in ypN0 Gastric Cancer Patients.
    Li W; Shao X; Ma F; Wang B; Xue L; Hu H; Kang W; Xiong J; Tian Y
    Oncol Res Treat; 2023; 46(7-8):287-295. PubMed ID: 37302386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.
    Hsu HY; Chao YK; Hsieh CH; Wen YW; Chang HK; Tseng CK; Liu YH
    Ann Thorac Surg; 2016 Nov; 102(5):1687-1693. PubMed ID: 27457831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Impact of Extracapsular Lymph Node Involvement in Esophageal Squamous Cell Carcinoma.
    Lin CM; Tu CC; Yeh YC; Hsu PK; Chien LI; Huang CS; Wu YC; Hsu HS
    Ann Surg Oncol; 2020 Aug; 27(8):3071-3082. PubMed ID: 32080808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.